Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 830

1.

JAK2 exon 12 mutation in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis: Not an exclusive mutation to polycythaemia vera.

Inano T, Araki M, Morishita S, Imai M, Yasuda H, Nitta H, Ito M, Edahiro Y, Ochiai T, Misawa K, Fukuda Y, Ohsaka A, Komatsu N.

Br J Haematol. 2019 Aug 16. doi: 10.1111/bjh.16146. [Epub ahead of print] No abstract available.

PMID:
31418453
2.

Vitamin B6 deficiency is prevalent in primary and secondary myelofibrosis patients.

Yasuda H, Tsutsui M, Ando J, Inano T, Noguchi M, Yahata Y, Tanaka M, Tsukune Y, Masuda A, Shirane S, Misawa K, Gotoh A, Sato E, Aritaka N, Sekiguchi Y, Sugimoto K, Komatsu N.

Int J Hematol. 2019 Aug 12. doi: 10.1007/s12185-019-02717-8. [Epub ahead of print]

PMID:
31407257
3.

[Efficacy and safety of ruxolitinib in patients with myelofibrosis: a single-center retrospective analysis].

Edahiro Y, Komatsu N.

Rinsho Ketsueki. 2019;60(7):755-760. doi: 10.11406/rinketsu.60.755. Japanese.

PMID:
31391362
4.

Long-term eradication of extranodal NK/T cell lymphoma, nasal type, by induced pluripotent stem cell-derived Epstein-Barr virus-specific rejuvenated T cells in vivo.

Ando M, Ando J, Yamazaki S, Ishii M, Sakiyama Y, Harada S, Honda T, Yamaguchi T, Nojima M, Ohshima K, Nakauchi H, Komatsu N.

Haematologica. 2019 Jul 11. pii: haematol.2019.223511. doi: 10.3324/haematol.2019.223511. [Epub ahead of print]

5.

Increased SLAMF7high monocytes in myelofibrosis patients harboring JAK2V617F provide a therapeutic target of elotuzumab.

Maekawa T, Kato S, Kawamura T, Takada K, Sone T, Ogata H, Saito K, Izumi T, Nagao S, Takano K, Okada Y, Tachi N, Teramoto M, Horiuchi T, Hikota-Saga R, Endo-Umeda K, Uno S, Osawa Y, Kobayashi A, Kobayashi S, Sato K, Hashimoto M, Suzu S, Usuki K, Morishita S, Araki M, Makishima M, Komatsu N, Kimura F.

Blood. 2019 Jul 3. pii: blood.2019000051. doi: 10.1182/blood.2019000051. [Epub ahead of print]

PMID:
31270105
6.

Preferential Tumor Accumulation of Polyglycerol Functionalized Nanodiamond Conjugated with Cyanine Dye Leading to Near-Infrared Fluorescence In Vivo Tumor Imaging.

Yoshino F, Amano T, Zou Y, Xu J, Kimura F, Furusho Y, Chano T, Murakami T, Zhao L, Komatsu N.

Small. 2019 Jul 1:e1901930. doi: 10.1002/smll.201901930. [Epub ahead of print]

PMID:
31259483
7.

Chemical functionalization of nanodiamonds: opportunities and challenges ahead.

Reina G, Zhao L, Bianco A, Komatsu N.

Angew Chem Int Ed Engl. 2019 Jun 27. doi: 10.1002/anie.201905997. [Epub ahead of print]

PMID:
31246341
8.

Malignant transformation from mature cystic teratoma of the ovary.

Shimada T, Higashijima A, Fukushima A, Komatsu N, Noguchi M, Ohashi K, Hasegawa Y, Miura K.

J Obstet Gynaecol Res. 2019 Jun 19. doi: 10.1111/jog.14043. [Epub ahead of print]

PMID:
31215124
9.

MRI-based risk factors of hepatocellular carcinoma in patients with chronic liver disease: A prospective observational study.

Shimizu T, Motosugi U, Komatsu N, Ichikawa S, Inoue T, Onishi H, Enomoto N.

J Magn Reson Imaging. 2019 May 23. doi: 10.1002/jmri.26797. [Epub ahead of print]

PMID:
31120640
10.

Hlf marks the developmental pathway for hematopoietic stem cells but not for erythro-myeloid progenitors.

Yokomizo T, Watanabe N, Umemoto T, Matsuo J, Harai R, Kihara Y, Nakamura E, Tada N, Sato T, Takaku T, Shimono A, Takizawa H, Nakagata N, Mori S, Kurokawa M, Tenen DG, Osato M, Suda T, Komatsu N.

J Exp Med. 2019 Jul 1;216(7):1599-1614. doi: 10.1084/jem.20181399. Epub 2019 May 10.

PMID:
31076455
11.
12.

Specific mechanisms of subarachnoid hemorrhage accompanied by ischemic stroke in essential thrombocythemia: two case reports and a literature review.

Sugiyama M, Ueno Y, Kamo H, Edahiro Y, Miyamoto N, Yamashiro K, Tanaka R, Shimo Y, Komatsu N, Hattori N.

J Neurol. 2019 Aug;266(8):1869-1878. doi: 10.1007/s00415-019-09347-4. Epub 2019 May 2.

PMID:
31049728
13.

Corrigendum to "Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib" [Leukemia Res. 79 (2019) 38-44].

Gerds AT, Tauchi T, Ritchie E, Deininger M, Jamieson C, Mesa R, Heaney M, Komatsu N, Minami H, Su Y, Shaik N, Zhang X, DiRienzo C, Zeremski M, Chan G, Talpaz M.

Leuk Res. 2019 Jun;81:105. doi: 10.1016/j.leukres.2019.04.006. Epub 2019 Apr 24. No abstract available.

PMID:
31029462
14.

Single-Cell Live Imaging.

Hiratsuka T, Komatsu N.

Methods Mol Biol. 2019;1979:409-421. doi: 10.1007/978-1-4939-9240-9_24.

PMID:
31028651
15.

Molecular features, prognosis, and novel treatment options for pediatric acute megakaryoblastic leukemia.

De Marchi F, Araki M, Komatsu N.

Expert Rev Hematol. 2019 May;12(5):285-293. doi: 10.1080/17474086.2019.1609351. Epub 2019 Apr 27.

PMID:
30991862
16.

Clinical and molecular features of patients with prefibrotic primary myelofibrosis previously diagnosed as having essential thrombocythemia in Japan.

Edahiro Y, Araki M, Inano T, Ito M, Morishita S, Misawa K, Fukuda Y, Imai M, Ohsaka A, Komatsu N.

Eur J Haematol. 2019 Jun;102(6):516-520. doi: 10.1111/ejh.13236. Epub 2019 Apr 25.

PMID:
30977935
17.

Smoking influences the outcomes of patients receiving tyrosine kinase inhibitors for chronic myeloid leukemia in the chronic phase: A retrospective analysis.

Iriyama N, Tokuhira M, Sato E, Sugimoto KJ, Takaku T, Ishikawa M, Nakazato T, Fujita H, Kimura Y, Fujioka I, Asou N, Komatsu N, Kizaki M, Hatta Y, Kawaguchi T.

Hematol Oncol. 2019 Apr 4. doi: 10.1002/hon.2617. [Epub ahead of print] No abstract available.

PMID:
30950076
18.

Evidence for prevention of renal dysfunction associated with primary myelofibrosis by cytoreductive therapy.

Fukuda Y, Araki M, Yamamoto K, Morishita S, Inano T, Misawa K, Ochiai T, Edahiro Y, Imai M, Yasuda H, Gotoh A, Ohsaka A, Komatsu N.

Haematologica. 2019 Apr 4. pii: haematol.2018.208876. doi: 10.3324/haematol.2018.208876. [Epub ahead of print]

19.

NUP98-HBO1-fusion generates phenotypically and genetically relevant chronic myelomonocytic leukemia pathogenesis.

Hayashi Y, Harada Y, Kagiyama Y, Nishikawa S, Ding Y, Imagawa J, Shingai N, Kato N, Kitaura J, Hokaiwado S, Maemoto Y, Ito A, Matsui H, Kitabayashi I, Iwama A, Komatsu N, Kitamura T, Harada H.

Blood Adv. 2019 Apr 9;3(7):1047-1060. doi: 10.1182/bloodadvances.2018025007.

20.

Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib.

Gerds AT, Tauchi T, Ritchie E, Deininger M, Jamieson C, Mesa R, Heaney M, Komatsu N, Minami H, Su Y, Shaik N, Zhang X, DiRienzo C, Zeremski M, Chan G, Talpaz M.

Leuk Res. 2019 Apr;79:38-44. doi: 10.1016/j.leukres.2019.02.012. Epub 2019 Feb 28. Erratum in: Leuk Res. 2019 Jun;81:105.

PMID:
30849661
21.

Acquired Factor VIII Inhibitor in a Patient of Rheumatoid Arthritis on Tumor Necrosis Factor Inhibitor Therapy.

Mori T, Watanabe N, Kitahara H, Iwao N, Koike M, Komatsu N.

Indian J Hematol Blood Transfus. 2019 Jan;35(1):192-193. doi: 10.1007/s12288-018-1030-1. Epub 2018 Oct 16. No abstract available.

22.

HBV preS deletion mapping using deep sequencing demonstrates a unique association with viral markers.

Suzuki Y, Maekawa S, Komatsu N, Sato M, Tatsumi A, Miura M, Matsuda S, Muraoka M, Nakakuki N, Amemiya F, Takano S, Fukasawa M, Nakayama Y, Yamaguchi T, Inoue T, Sato T, Sakamoto M, Yamashita A, Moriishi K, Enomoto N.

PLoS One. 2019 Feb 22;14(2):e0212559. doi: 10.1371/journal.pone.0212559. eCollection 2019.

23.

Size-tunable MRI-visible nitroxide-based magnetic mixed micelles: preparation, stability, and theranostic application.

Nagura K, Bogdanov A, Chumakova N, Vorobiev AK, Moronaga S, Imai H, Matsuda T, Noda Y, Maeda T, Koizumi S, Sakamoto K, Amano T, Yoshino F, Kato T, Komatsu N, Tamura R.

Nanotechnology. 2019 May 31;30(22):224002. doi: 10.1088/1361-6528/ab0627. Epub 2019 Feb 11.

PMID:
30743248
24.

Phase II study of FLAGM (fludarabine + high-dose cytarabine + granulocyte colony-stimulating factor + mitoxantrone) for relapsed or refractory acute myeloid leukemia.

Hatsumi N, Miyawaki S, Yamauchi T, Takeshita A, Komatsu N, Usui N, Arai Y, Ishida F, Morii T, Kano Y, Ogura M, Machida S, Nishii K, Honda S, Ohnishi K, Naoe T; Japan Adult Leukemia Study Group (JALSG).

Int J Hematol. 2019 Apr;109(4):418-425. doi: 10.1007/s12185-019-02606-0. Epub 2019 Feb 6.

PMID:
30725360
25.

Doxorubicin conjugated with nanodiamonds and in free form commit glioblastoma cells to heterodromous fates.

Chen Z, Wang C, Li TF, Li K, Yue Y, Liu X, Xu HZ, Wen Y, Zhang Q, Han M, Komatsu N, Xu YH, Zhao L, Chen X.

Nanomedicine (Lond). 2019 Feb;14(3):335-351. doi: 10.2217/nnm-2018-0330. Epub 2019 Jan 24.

PMID:
30676239
26.

Magnetic Mixed Micelles Composed of a Non-Ionic Surfactant and Nitroxide Radicals Containing a D-Glucosamine Unit: Preparation, Stability, and Biomedical Application.

Nagura K, Takemoto Y, Yoshino F, Bogdanov A, Chumakova N, Vorobiev AK, Imai H, Matsuda T, Shimono S, Kato T, Komatsu N, Tamura R.

Pharmaceutics. 2019 Jan 19;11(1). pii: E42. doi: 10.3390/pharmaceutics11010042.

27.

Doxorubicin-polyglycerol-nanodiamond composites stimulate glioblastoma cell immunogenicity through activation of autophagy.

Li TF, Xu YH, Li K, Wang C, Liu X, Yue Y, Chen Z, Yuan SJ, Wen Y, Zhang Q, Han M, Komatsu N, Zhao L, Chen X.

Acta Biomater. 2019 Mar 1;86:381-394. doi: 10.1016/j.actbio.2019.01.020. Epub 2019 Jan 14.

PMID:
30654213
28.

Type I collagen deposition via osteoinduction ameliorates YAP/TAZ activity in 3D floating culture clumps of mesenchymal stem cell/extracellular matrix complexes.

Komatsu N, Kajiya M, Motoike S, Takewaki M, Horikoshi S, Iwata T, Ouhara K, Takeda K, Matsuda S, Fujita T, Kurihara H.

Stem Cell Res Ther. 2018 Dec 7;9(1):342. doi: 10.1186/s13287-018-1085-9.

29.

A randomized, double-blind, phase III trial of personalized peptide vaccination for recurrent glioblastoma.

Narita Y, Arakawa Y, Yamasaki F, Nishikawa R, Aoki T, Kanamori M, Nagane M, Kumabe T, Hirose Y, Ichikawa T, Kobayashi H, Fujimaki T, Goto H, Takeshima H, Ueba T, Abe H, Tamiya T, Sonoda Y, Natsume A, Kakuma T, Sugita Y, Komatsu N, Yamada A, Sasada T, Matsueda S, Shichijo S, Itoh K, Terasaki M.

Neuro Oncol. 2019 Feb 19;21(3):348-359. doi: 10.1093/neuonc/noy200.

PMID:
30500939
30.

Mutant molecular chaperone activates cytokine receptor as a homomultimer.

Araki M, Komatsu N.

Oncotarget. 2018 Oct 16;9(81):35201-35202. doi: 10.18632/oncotarget.26221. eCollection 2018 Oct 16. No abstract available.

31.

Enteral self-expandable metal stent placement for malignant afferent limb syndrome using single-balloon enteroscope: report of five cases.

Yane K, Katanuma A, Hayashi T, Takahashi K, Kin T, Nagai K, Tanaka K, Komatsu N, Endo M, Kobayashi Y, Takigawa Y, Utsunomiya R.

Endosc Int Open. 2018 Nov;6(11):E1330-E1335. doi: 10.1055/a-0739-7640. Epub 2018 Nov 7.

32.

Clinical impact of serum soluble SLAMF7 in multiple myeloma.

Ishibashi M, Soeda S, Sasaki M, Handa H, Imai Y, Tanaka N, Tanosaki S, Ito S, Odajima T, Sugimori H, Asayama T, Sunakawa M, Kaito Y, Kinoshita R, Kuribayashi Y, Onodera A, Moriya K, Tanaka J, Tsukune Y, Komatsu N, Inokuchi K, Tamura H.

Oncotarget. 2018 Oct 5;9(78):34784-34793. doi: 10.18632/oncotarget.26196. eCollection 2018 Oct 5.

33.

Impact of splicing factor mutations on clinical features in patients with myelodysplastic syndromes.

Shingai N, Harada Y, Iizuka H, Ogata Y, Doki N, Ohashi K, Hagihara M, Komatsu N, Harada H.

Int J Hematol. 2018 Dec;108(6):598-606. doi: 10.1007/s12185-018-2551-y. Epub 2018 Oct 23.

PMID:
30353274
34.

Hepatitis B virus (HBV)-infected patients with low hepatitis B surface antigen and high hepatitis B core-related antigen titers have a high risk of HBV-related hepatocellular carcinoma.

Suzuki Y, Maekawa S, Komatsu N, Sato M, Tatsumi A, Miura M, Matsuda S, Muraoka M, Nakakuki N, Shindo H, Amemiya F, Takano S, Fukasawa M, Nakayama Y, Yamaguchi T, Inoue T, Sato T, Sakamoto M, Yamashita A, Moriishi K, Enomoto N.

Hepatol Res. 2019 Jan;49(1):51-63. doi: 10.1111/hepr.13277. Epub 2018 Dec 27.

PMID:
30350374
35.

High interleukin-8 level in aqueous humor is associated with poor prognosis in eyes with open angle glaucoma and neovascular glaucoma.

Chono I, Miyazaki D, Miyake H, Komatsu N, Ehara F, Nagase D, Kawamoto Y, Shimizu Y, Ideta R, Inoue Y.

Sci Rep. 2018 Sep 28;8(1):14533. doi: 10.1038/s41598-018-32725-3.

36.

Administration of plasma-derived coagulation factor VIII during the perioperative period of mastectomy for breast cancer with acquired von Willebrand syndrome.

Sasaki R, Horimoto Y, Mizuno J, Edahiro Y, Ohmori T, Komatsu N, Saito M.

Surg Case Rep. 2018 Sep 17;4(1):118. doi: 10.1186/s40792-018-0528-y.

37.

Comparison of the clinical outcomes of nilotinib and dasatinib therapies in newly diagnosed patients in the chronic phase of chronic myeloid leukemia: a retrospective analysis.

Iriyama N, Sugimoto KJ, Sato E, Takaku T, Tokuhira M, Nakazato T, Ishikawa M, Fujita H, Fujioka I, Kimura Y, Asou N, Kizaki M, Komatsu N, Hatta Y, Kawaguchi T.

Med Oncol. 2018 Sep 7;35(11):142. doi: 10.1007/s12032-018-1203-7.

PMID:
30194496
38.

Dasatinib-induced anti-leukemia cellular immunity through a novel subset of CD57 positive helper/cytotoxic CD4 T cells in chronic myelogenous leukemia patients.

Watanabe N, Takaku T, Takeda K, Shirane S, Toyota T, Koike M, Noguchi M, Hirano T, Fujiwara H, Komatsu N.

Int J Hematol. 2018 Dec;108(6):588-597. doi: 10.1007/s12185-018-2517-0. Epub 2018 Aug 27.

PMID:
30151740
39.

Multiple Placental Infarcts in a Pregnant Woman with Essential Thrombocythemia.

Edahiro Y, Ando J, Suzuki T, Fukumura Y, Masuda A, Sakayori S, Takeda J, Maruyama Y, Makino S, Itakura A, Komatsu N.

Intern Med. 2018 Dec 15;57(24):3647-3650. doi: 10.2169/internalmedicine.1311-18. Epub 2018 Aug 10.

40.

[iPSC-derived rejuvenated T-cell therapy for Epstein-Barr virus-associated lymphomas].

Ando M, Nakauchi H, Komatsu N.

Rinsho Ketsueki. 2018;59(7):932-938. doi: 10.11406/rinketsu.59.932. Japanese.

PMID:
30078805
41.

[Recurrent amylase-producing multiple myeloma responding to pomalidomide and carfilzomib-containing therapies].

Aota Y, Gotoh A, Okuda Y, Honda T, Watanabe N, Ando J, Komatsu N.

Rinsho Ketsueki. 2018;59(7):865-871. doi: 10.11406/rinketsu.59.865. Japanese.

PMID:
30078795
42.

Dendritic cell-mediated delivery of doxorubicin-polyglycerol-nanodiamond composites elicits enhanced anti-cancer immune response in glioblastoma.

Li TF, Li K, Zhang Q, Wang C, Yue Y, Chen Z, Yuan SJ, Liu X, Wen Y, Han M, Komatsu N, Xu YH, Zhao L, Chen X.

Biomaterials. 2018 Oct;181:35-52. doi: 10.1016/j.biomaterials.2018.07.035. Epub 2018 Jul 26.

PMID:
30071380
43.

Correction to "Direct Fabrication of the Graphene-Based Composite for Cancer Phototherapy through Graphite Exfoliation with a Photosensitizer".

Liu G, Qin H, Amano T, Murakami T, Komatsu N.

ACS Appl Mater Interfaces. 2018 Aug 8;10(31):26813. doi: 10.1021/acsami.8b11270. Epub 2018 Jul 26. No abstract available.

PMID:
30048105
44.

Immune-bone interplay in the structural damage in rheumatoid arthritis.

Komatsu N, Takayanagi H.

Clin Exp Immunol. 2018 Oct;194(1):1-8. doi: 10.1111/cei.13188. Epub 2018 Sep 4. Review.

PMID:
30022480
45.

Pleural effusion at diagnosis predicts extremely poor outcomes in patients with diffuse large B-cell lymphoma harbouring MYC rearrangement.

Nitta H, Gotoh A, Tanaka M, Sekiguchi Y, Ota Y, Noguchi M, Komatsu N.

Br J Haematol. 2019 Apr;185(1):183-187. doi: 10.1111/bjh.15431. Epub 2018 Jul 5. No abstract available.

PMID:
29974930
46.

[A novel quantitative JAK2V617F detection kit: prospective clinical performance study comparing MPN patients and healthy subjects].

Kirito K, Koike M, Noguchi M, Kizaki M, Katayama N, Sugimoto Y, Dobashi N, Usui N, Komatsu N.

Rinsho Ketsueki. 2018;59(6):669-674. doi: 10.11406/rinketsu.59.669. Japanese.

PMID:
29973441
47.

Features of vascular adverse events in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a retrospective study of the CML Cooperative Study Group database.

Fujioka I, Takaku T, Iriyama N, Tokuhira M, Kimura Y, Sato E, Ishikawa M, Nakazato T, Sugimoto KJ, Fujita H, Asou N, Kizaki M, Hatta Y, Komatsu N, Kawaguchi T.

Ann Hematol. 2018 Nov;97(11):2081-2088. doi: 10.1007/s00277-018-3412-8. Epub 2018 Jun 26.

PMID:
29946911
48.

Homomultimerization of mutant calreticulin is a prerequisite for MPL binding and activation.

Araki M, Yang Y, Imai M, Mizukami Y, Kihara Y, Sunami Y, Masubuchi N, Edahiro Y, Hironaka Y, Osaga S, Ohsaka A, Komatsu N.

Leukemia. 2019 Jan;33(1):122-131. doi: 10.1038/s41375-018-0181-2. Epub 2018 Jun 26.

PMID:
29946189
49.

Efficacy of PCR-based open reading frame typing assay for outbreak investigation of metallo-β-lactamase-producing Pseudomonas aeruginosa in hematology unit.

Nakamura A, Misawa S, Chonan M, Kawakami T, Horii T, Komatsu N, Ohsaka A.

J Infect Chemother. 2018 Dec;24(12):1020-1023. doi: 10.1016/j.jiac.2018.06.002. Epub 2018 Jun 23.

PMID:
29941274
50.

Retroperitoneal relapse in an older patient with multiple myeloma during pomalidomide and dexamethasone treatment.

Watanabe N, Kitahara H, Iwao N, Ohta Y, Koike M, Komatsu N.

Geriatr Gerontol Int. 2018 Jun;18(6):977-979. doi: 10.1111/ggi.13298. No abstract available.

PMID:
29924492

Supplemental Content

Loading ...
Support Center